Literature DB >> 2920949

Endometrial adenocarcinoma histologic subtypes: clinical and pathologic profile.

J Fanning1, M C Evans, A J Peters, M Samuel, E R Harmon, J S Bates.   

Abstract

All cases of endometrial adenocarcinoma treated at the Geisinger Medical Center from January 1970 to June 1980 were retrospectively reviewed in an attempt to elucidate the clinical and pathologic profiles of the various histologic subtypes. Complete clinical and pathologic data was available in 418 cases of stage I endometrial adenocarcinoma. The frequency of the histologic subtypes were adenocarcinoma 66%, adenoacanthoma 16%, adenosquamous 5%, papillary 8%, clear cell 3%, and secretory 2%. Absolute 5-year survival was adenocarcinoma 88%, adenoacanthoma 91%, adenosquamous 62%, papillary 63% (P less than 0.01), clear cell 43% (P less than 0.001), and secretory 89%. When comparing the clinical and pathologic profile of the various histologic subtypes, adenosquamous (52%, P less than 0.001) and clear cell (43%, P less than 0.05) were associated with the highest percentage of grade 3 differentiation. Adenosquamous (38%, P less than 0.05) and clear cell (36%) also had the highest percentage of deep myometrial invasion. Papillary subtype (46%, P less than 0.05) was associated with the highest percentage of nulliparity. There was no difference among the subtypes when comparing menopausal status, exogenous estrogen, obesity, hypertension, diabetes, or uterine size. In summary, (1) adenocarcinoma and adenoacanthoma are the most frequent subtypes; (2) adenosquamous, papillary, and clear cell have decreased 5-year survival; (3) the decreased 5-year survival in adenosquamous and clear cell subtypes appears to be associated with increased grade 3 differentiation and deep myometrial invasion while the poor prognosis associated with papillary subtype was not related to grade or myometrial invasion.

Entities:  

Mesh:

Year:  1989        PMID: 2920949     DOI: 10.1016/0090-8258(89)90626-4

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Induction of apoptosis in endometrial cancer cells by psammaplysene A involves FOXO1.

Authors:  Emily Berry; Jennifer L Hardt; Jon Clardy; John R Lurain; J Julie Kim
Journal:  Gynecol Oncol       Date:  2008-11-28       Impact factor: 5.482

2.  Is Adjuvant Chemotherapy Necessary in Patients with Early Endometrial Cancer?

Authors:  Yuki Iida; Hiroaki Komatsu; Masayo Okawa; Daiken Osaku; Kanae Nosaka; Shinya Sato; Tetsuro Oishi; Fuminori Taniguchi; Tasuku Harada
Journal:  Yonago Acta Med       Date:  2022-02-22       Impact factor: 1.641

3.  Evaluation of Survival, Recurrence Patterns and Adjuvant Therapy in Surgically Staged High-Grade Endometrial Cancer with Retroperitoneal Metastases.

Authors:  Jennifer McEachron; Lila Marshall; Nancy Zhou; Van Tran; Margaux J Kanis; Constantine Gorelick; Yi-Chun Lee
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

4.  Efficacy of endocervical curettage and CA-125 measurement in endometrial serous carcinoma: A case series and literature review.

Authors:  Ahmet Cem İyibozkurt; Murat Doğan; Ercan Baştu; Hamdullah Sözen; Doğan Vatansever; Samet Topuz; Sinan Berkman
Journal:  Turk J Obstet Gynecol       Date:  2015-09-15

5.  Hospital-based study of epithelial malignancies of endometrial cancer frequency in lahore, pakistan, and common diagnostic pitfalls.

Authors:  Imrana Tanvir; Sabiha Riaz; Afshan Hussain; Riffat Mehboob; M Usman Shams; Haseeb Ahmad Khan
Journal:  Patholog Res Int       Date:  2014-01-06

6.  ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target.

Authors:  Dongli Liu; Kate Gunther; Luis A Enriquez; Benjamin Daniels; Tracy A O'Mara; Katrina Tang; Amanda B Spurdle; Caroline E Ford
Journal:  Sci Rep       Date:  2020-08-17       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.